Illumina (NASDAQ:ILMN) PT Lowered to $242.00

Illumina (NASDAQ:ILMN) had its target price decreased by equities research analysts at Royal Bank of Canada from $249.00 to $242.00 in a research report issued on Monday, Benzinga reports. The firm presently has an “outperform” rating on the life sciences company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 125.54% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. Evercore ISI lowered their target price on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research note on Tuesday, June 11th. Scotiabank lowered their target price on Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a research note on Monday, May 6th. OTR Global reiterated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. TD Cowen lowered their target price on Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research note on Thursday, June 6th. Finally, Jefferies Financial Group began coverage on Illumina in a research note on Monday, June 3rd. They issued a “hold” rating and a $115.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $157.62.

Illumina Trading Up 2.8 %

NASDAQ ILMN traded up $2.92 during trading hours on Monday, hitting $107.30. 173,540 shares of the company’s stock were exchanged, compared to its average volume of 2,176,718. The business’s 50 day moving average is $111.62 and its 200-day moving average is $127.32. Illumina has a 12-month low of $89.00 and a 12-month high of $195.64. The firm has a market capitalization of $17.09 billion, a P/E ratio of -13.22 and a beta of 1.20. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same period last year, the business posted $0.08 EPS. As a group, analysts anticipate that Illumina will post 0.98 EPS for the current fiscal year.

Institutional Trading of Illumina

Hedge funds have recently made changes to their positions in the stock. Trivant Custom Portfolio Group LLC lifted its holdings in shares of Illumina by 166.7% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after purchasing an additional 125 shares during the last quarter. VisionPoint Advisory Group LLC boosted its position in Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 193 shares during the period. Wetzel Investment Advisors Inc. acquired a new position in Illumina during the 4th quarter worth $37,000. Massmutual Trust Co. FSB ADV boosted its position in Illumina by 86.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after acquiring an additional 132 shares during the period. Finally, Gradient Investments LLC boosted its position in Illumina by 375.0% during the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after acquiring an additional 225 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.